Atopic dermatitis clinical trials market seen reaching $4.78 billion by 2030

The atopic dermatitis clinical trials market is projected to grow from $2.74 billion in 2025 to $3.07 billion in 2026, with stronger demand for biologics, JAK inhibitors and decentralized studies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - The market reflects rising demand for new treatments for atopic dermatitis, a chronic inflammatory skin disease that affects symptoms, flare-ups and quality of life. - Growth in clinical trials can speed development of biologics, JAK inhibitors and other therapies that may expand treatment options for patients. - The forecast points to sustained investment in dermatology research and trial infrastructure through the end of the decade.

What happened: - The Business Research Company released its Atopic Dermatitis Clinical Trials Global Market Report 2026, covering market size, trends and a 2026-2035 outlook. - The report values the market at $2.74 billion in 2025 and projects $3.07 billion in 2026. - The report forecasts the market will reach $4.78 billion by 2030. - The report says the market is growing at 12.0% in 2026 and is expected to grow at a 11.7% compound annual rate through 2030. - The report highlights North America as the largest regional market in 2025. - The report identifies Asia-Pacific as the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes a free sample and the full market report.

The details: - Atopic dermatitis clinical trials test new and existing therapies, including drugs, biologics and topical agents. - The trials measure symptom relief, fewer flare-ups and better quality of life. - The report cites rising incidence of atopic dermatitis as one driver of recent market growth. - Broader dermatology drug pipelines have also supported expansion. - More spending on clinical research and stronger participation from contract research organizations have boosted trial activity. - Improved trial design and conduct have added to market momentum. - The report points to strong demand for innovative biologic treatments and JAK inhibitors as a major driver of future growth. - The report also flags wider use of decentralized clinical trials, real-world evidence and personalized therapies. - More regulatory approvals for advanced treatments are expected to support future demand. - Pharmaceutical and biopharma investment remains a major growth catalyst because it funds research, development, manufacturing and commercialization. - The Association of Australian Medical Research Institutes reported in December 2024 that Australian medical research institutes received close to AUD 2.5 billion, or about USD 1.65 billion, in total revenue in 2023.

Between the lines: - The report suggests the market is moving from broad dermatology research toward more targeted and data-driven trial models. - North America's lead reflects established research infrastructure and a strong pharmaceutical base. - Asia-Pacific's faster growth likely points to expanding clinical research capacity and a larger pipeline of trial activity in the region. - The emphasis on decentralized trials and real-world evidence shows that trial operations are changing, not just the therapies under study.

What's next: - The market is expected to keep expanding as companies pursue new biologics, JAK inhibitors and personalized approaches. - More decentralized studies and real-world evidence could reshape how atopic dermatitis trials are designed and run. - Additional regulatory approvals may increase the number of advanced treatments moving through clinical development. - The Business Research Company said expanded 2026 reports will include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspots infographics, key technology analysis and updated graphics and tables.